Etanercept-induced lichenoid reaction pattern in psoriasis

被引：15

作者：

Bovenschen, H. Jorn ^{[1
]}

Kop, Else N. ^{[1
]}

Van de Kerkhof, Peter C. M. ^{[1
]}

Seyger, Marieke M. B. ^{[1
]}

机构：

[1] Radboud Univ Nijmegen, Dept Dermatol, Nijmegen, Netherlands

来源：

JOURNAL OF DERMATOLOGICAL TREATMENT | 2006年 / 17卷 / 06期

关键词：

anti-TNF alpha; drug eruption; etanercept;

D O I：

10.1080/09546630600967174

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

We describe a patient with severe psoriasis who was treated with 25 mg subcutaneous etanercept, twice weekly, after several traditional topical and systemic treatments had failed. Our patient initially responded well to etanercept, but after 5 weeks she developed remarkable purple, sharply demarcated, erythematosquamous plaques on the dorsa of both hands, wrists and proximal fingers. Histology showed apoptotic cells and basal vacuolization in addition to a histological picture consistent with moderately active psoriasis. Discontinuation of the drug resulted in a slow regression of the eruption. It is important to realize that a lichenoid reaction pattern may occur during anti-TNF alpha. agent treatment.

引用

页码：381 / 383

页数：3

共 16 条

[1] Etanercept-induced subacute cutaneous lupus erythematosus [J].

Bleumink, GS ;

ter Borg, EJ ;

Ramselaar, CG ;

Stricker, BHC .

RHEUMATOLOGY, 2001, 40 (11) :1317-1319

[2] Induction of eruptive benign melanocytic naevi by immune suppressive agents, including biologicals [J].

Bovenschen, HJ ;

Tjioe, M ;

Vermaat, H ;

de Hoop, D ;

Witteman, BMJ ;

Janssens, RWA ;

Stoof, TJ ;

van de Kerkhof, PCM .

BRITISH JOURNAL OF DERMATOLOGY, 2006, 154 (05) :880-884

[3] Etanercept and squamous cell carcinoma [J].

Burge, D .

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2003, 49 (02) :358-359

[4] Dermatological conditions during TNF-α-blocking therapy in patients with rheumatoid arthritis:: a prospective study [J].

Flendrie, M ;

Vissers, WHPM ;

Creemers, MCW ;

de Jong, EMGJ ;

van de Kerkhof, PCM ;

van Riel, PLCM .

ARTHRITIS RESEARCH & THERAPY, 2005, 7 (03) :R666-R676

[5]

GILLUM PS, 1998, TXB DERMATOPATHOLOGY, P55

[6] Bullous skin lesions following infliximab infusion in a patient with rheumatoid arthritis [J].

Kent, PD ;

Davis, JM ;

Davis, MDP ;

Matteson, EL .

ARTHRITIS AND RHEUMATISM, 2002, 46 (08) :2257-2258

[7] Etanercept as monotherapy in patients with psoriasis [J].

Leonardi, CL ;

Powers, JL ;

Matheson, RT ;

Goffe, BS ;

Zitnik, R ;

Wang, A ;

Gottlieb, AB ;

Bagel, J ;

Camisa, C ;

Caro, I ;

DiGiovanna, JJ ;

Dunlap, FF ;

Elewski, BE ;

Gribetz, CE ;

Farber, HF ;

Feldman, SR ;

Frankel, EH ;

Gaspari, AA ;

Goodman, JJ ;

Gordon, KB ;

Hampel, FC ;

Herdener, RS ;

Hoffman, MD ;

Humeniuk, JM ;

Johnson, SM ;

Kang, S ;

Kimball, AB ;

Kirsner, RS ;

Korman, NJ ;

Krueger, GG ;

Kuwahara, RT ;

Lebwohl, M ;

Ling, MR ;

Liu, DC ;

Lowe, N ;

McCall, CO ;

Menter, A ;

Miller, BH ;

Moore, JK ;

Nayak, AS ;

Ratner, PH ;

Savin, RC ;

Shupack, JL ;

Smith, SL ;

Stone, SP ;

Swinehart, JM ;

Taborn, J ;

Tschen, EH ;

Weinstein, GD ;

Werth, VP .

NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (21) :2014-2022

[8] Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial [J].

Mease, PJ ;

Goffe, BS ;

Metz, J ;

VanderStoep, A ;

Finck, B ;

Burge, DJ .

LANCET, 2000, 356 (9227) :385-390

[9]

Patel Toral, 2004, Dermatol Ther, V17, P427, DOI 10.1111/j.1396-0296.2004.04045.x

[10] Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial [J].

Reich, K ;

Nestle, FO ;

Papp, K ;

Ortonne, JP ;

Evans, R ;

Guzzo, C ;

Li, S ;

Dooley, LT ;

Griffiths, CEM .

LANCET, 2005, 366 (9494) :1367-1374

← 1 2 →